Associations between cellular immune effector function, iron metabolism, and disease activity in patients with chronic hepatitis C virus infection

Journal of Infectious Diseases

Volumn 180, Issue 5, 1999, Pages 1452-1458

  Weiss, Günter ^a   Umlauft, Florian ^a   Urbanek, Martina ^a   Herold, Manfred ^a   Lovevsky, Mark ^c   Offner, Felix ^b   Gordeuk, Victor R ^c  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^c GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; FERRITIN; INTERLEUKIN 10; INTERLEUKIN 4; NEOPTERIN; TRANSFERRIN; TUMOR NECROSIS FACTOR RECEPTOR;

ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOMODULATION; IRON METABOLISM; LIVER CIRRHOSIS; LIVER DYSFUNCTION; MACROPHAGE ACTIVATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

ANTIGENS, CD; CASE-CONTROL STUDIES; DISEASE PROGRESSION; FERRITINS; HEPATITIS C, CHRONIC; HUMANS; INTERLEUKINS; IRON; LIVER; LIVER CIRRHOSIS; MACROPHAGE ACTIVATION; NEOPTERIN; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; T-LYMPHOCYTES, HELPER-INDUCER; TRANSFERRIN;

EID: 0032721955     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315052     Document Type: Article

References (43)

1. 1. Alter MJ, Sampliner RE. Hepatitis C. And miles to go before we sleep (editorial). N Engl J Med 1989; 321:1538-40.
2. 2. Romagnani S. The Th1/Th2 paradigm. Immunol Today 1997; 18:263-6.
3. 3. Bogdan C, Vodovotz Y, Paik J, Xie QW, Nathan C. Mechanism of suppression of nitric oxide synthase by interleukin-4 in primary mouse macrophages. J Leukoc Biol 1994; 55:227-32.
4. 4. Powric F, Menon S, Coffman RL. Interleukin-4 and interleukin-10 synergize to inhibit cell-mediated immunity in vivo. Eur J Immunol 1993; 23:2223-9.
5. 5. Akiyoshi F, Sata M, Uchimara Y, Suzuki H, Tanikawa K. Hepatic iron stainings in chronic hepatitis C patients with low HCV RNA levels: a predictive marker for IFN therapy. Am J Gastroenterol 1997; 92:1463-6.
6. 6. Barton AL, Banner B, Cable ED, Bonkovsky HL. Distribution of iron in the liver predicts the response of chronic hepatitis C infection to interferon therapy. Am J Clin Pathol 1995; 103:419-24.
7. 7. Farigon S, Fracabzani AL, Sampietro M, et al. Liver iron influences the response to interferon alpha therapy in chronic hepatitis C. Eur J Gastroenterol Hepatol 1997; 9:497-503.
8. 8. Piperino A, Sampietro M, D'Alba R, et al. Iron stores, response to alpha interferon therapy and effects of iron depletion in chronic hepatitis C. Liver 1996; 16:248-54.
9. 9. Brock JH. Iron in infection, immunity, inflammation and neoplasia. In: Brock JH, Halliday JW, Pippard MJ, Powell LW, eds. Iron Metabolism in Health and Disease. Philadelphia: WB Saunders, 1994:353-90.
10. 10. Weiss G, Wachter H, Fuchs D. Linkage of cellular immunity to iron metabolism. Immunol Today 1995; 16:495-500.
11. 11. Weiss G, Fuchs D, Hausen A, et al. Iron modulates interferon-gamma effects in human myelomonocytic cell line THP-1. Exp Hematol 1992; 20:605-10.
12. 12. Alford CE, King TE, Campell PA. Role of transferrin, transferrin receptors and iron in macrophage listericidal activity. J Exp Med 1991; 174:459-67.
13. 13. Barnewell RE, Rikihias Y. Abrogation of gamma interferon-induced inhibition of Ehrlichia chaffeensis infection in human monocytes with transferrin iron. Infect Immun 1994; 82:4804-10.
14. 14. Byrd TF, Horwitz MA. Lactoferrin inhibits or promotes Legionella pneumophila intracellular multiplication in nonactivated and interferon-gamma activated human monocytes depending upon ist degree of iron saturation: iron-lactoferrin and nonphysiologic iron chelates reverse monocyte activation against Legionella pneumophila. J Clin Invest 1991; 88:1103-12.
15. 15. Karupiah G, Harris N. Inhibition of viral replication by nitric oxide and its reversal by ferrous sulfate and tricarboxylic acid cycle metabolites. J Exp Med 1995; 181:2171-9.
16. 16. Weiss G, Thuma P, Mabeza R, Werner ER, Herold M, Gordeuk V. Modulatory effects of iron chelation therapy on nitric oxide formation in children with cerebral malaria. J Infect Dis 1997; 175:226-30.
17. 17. Menacci A, Cenci E, Boelaert JR, et al. Iron overload alters T helper cell responses to Candida albicans in mice. J Infect Dis 1997; 175:1467-76.
18. 18. Thuma PE, Weiss G, Herold M, Gordeuk VR. Serum neopterin, interleukin-4 and interleukin 6 concentrations in cerebral malaria patients and the effect of iron chelation therapy. Am J Trop Med Hyg 1996; 54:164-8.
19. 19. Weiss G, Werner-Felmayer G, Werner ER, Grünewald K. Wachter H, Hentze MW. Iron regulates nitric oxide synthase activity by controlling nuclear transcription. J Exp Med 1994; 180:969-76.
20. 20. Xie QW, Cho H, Calaycay J, et al. Cloning and characterization of inducible nitric oxide synthase from mouse macrophages. Science 1992; 256:225-8.
21. 21. Geller DA, Lowenstein C, Shapiro RA, et al. Molecular cloning and expression of inducible nitric oxide synthase from human hepatocytes. Proc Natl Acad Sci USA 1993; 90:3491-5.
22. 22. Karupiah G, Xie QW. Buller RM, Nathan C, Duarte C, MacMicking JD. Inhibition of viral replication by interferon-gamma induced nitric oxide synthase. Science 1993; 261:1445-8.
23. 23. Weinberg ED, Weinberg GA. The role of iron in infection. Curr Opin Infect Dis 1995; 8:164-9.
24. 24. Jazwinska EC, Cullen LM, Busfield F, et al. Haemochromatosis and HLA-H. Nat Genet 1996; 14:249-51.
25. 25. Umlauft F, Grünewald K, Weiss G, et al. Patterns of Hepatitis C viremia in hemodialysis patients. Am J Gastroenterol 1997; 92:73-8.
26. 15N]nitrite in biological fluids. Ann Biochem 1982; 126:131-8.
27. 27. Torrance JD, Bothwell TH. Tissue iron stores. In: Cook JD, ed. Iron. New York: Churchill Livingstone 1980: 90-115.
28. 28. Thomas L. Labor und Diagnose. 3rd ed. Marburg, Germany: Medizinische Verlagsgeschellsehaft. 1988:387-400.
29. 29. Huber C, Batchelor JR, Fuchs D, et al. Immune response associated production of neopterin. J Exp Med 1984; 160:310-6.
30. 30. Fuchs D, Hausen A, Reibnegger G, Werner ER, Wachter H. Neopterin as a marker of activated cell-mediated immunity, application on HlV-infection. Immunol Today 1988; 9:150-5.
31. 31. Prior C, Fuchs D, Hausen A, et al. Potential of urinary neopterin excretion in differentiating chronic non-A, non-B hepatitis from fatty liver. Lancet 1987; 2:1235-7.
32. 32. Reibnegger G, Weiss G, Werner-Felmayer G, Judmaier G, Wachter H. Neural networks as a tool for utilizing laboratory information: comparison with linear discriminant analysis and with classification and regression trees, Proc Nalt Acad Sci USA 1991; 88:11426-30.
33. 33. Napoli J, Bishop A. McGuinness PH, Paintner DM, McCAughan GW. Progressive liver injury in chronic hepatitis C infection correlates with increased intrahepatic expression of Th-1 associated cytokines. Hepatology 1996; 24:759-65.
34. 34. Diez-Ruiz A, Tilz GP, Zangerle R, Baier-Bitterlich G, Wachter H, Fuchs D. Soluble reecptors for tumor necrosis fuctor in clinical laboratory diagnosis. Eur J Haematol 1995; 54:1-8.
35. 35. Bomford AB, Munro HN. Ferritin gene expression in health and malignancy. Pathobiology 1992; 60:10-18.
36. 36. Pietrangelo A. Metals, oxidative stress, and hepatic fibrogenesis. Semin Liv Dis 1996; 16:13-30.
37. 37. Mihm S, Fayyazi A, Ramadori G. Hepatic expression of inducible nitric oxide synthase transcripts in chronic hepatitis C virus infection: relation tlo hepatic viral load and liver injury. Hepatology 1997; 26:451-8.
38. 38. Sharara AI, Perkins DJ, Misukonis MA, Chan SU, Dominitz JA, Weinberg JB. Interferon (IFN)-alpha activation of human blood mononuclear cells in vitro and in vivo for nitric oxide synthase (NOS) type 2 mRNA and protein expression: possible relationship of induced NOS2 to the antihepatitis C effects of IFN-alpha in vivo. J Exp Med 1997; 186:1495-502.
39. 39. Ivashkiv LB. Cytokine and STATs: how can signals achieve specificity? Immunity 1995; 3:1-8.
40. 40. Beinker NK, Voigt MD, Arendse M, Smit J, Stander IA, Kirsch RE. Threshold effect of liver iron content on hepatic inflammation and fibrosis in hepatitis B and C. J Hepatol 1996; 25:633-8.
41. 41. Gordeuk VR, Thuma PE, Brittenham G, et al. Effect of iron chelation therapy on recovery from deep coma in children with cerebral malaria. N Engl J Med 1992; 327:1473-7.
42. 42. Tsai NC, Zuckerman E, Han SH, Goad K, Redeker AG, Fong TL. Effect of iron depletion on long term response to interferon-alpha in patients with chronic hepatitis C who previously did not respond to interferon therapy. Am J Gastroenterol 1997; 92:1831-4.
43. 43. Pietrangelo A, Gualdi R, Casalgrandi G, Montosi G, Ventura E. Molecular and cellular aspects of iron induced hepatic cirrhosis in rodents. J Clin Invest 1995; 95:1824-31.